ArticleBioMed research international2016
Tanshinone IIA Alleviates the AD Phenotypes in APP and PS1 Transgenic Mice.
Article in BioMed research international, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Preclinical evidence and potential mechanisms of tanshinone ⅡA on cognitive function in animal models of Alzheimer's disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- The effect of tanshinones on cognitive impairments in animal models of Alzheimer's disease: a systematic review and meta-analysis.Frontiers in pharmacology · 2025Pooled it
- Tanshinone IIA suppresses cancer metastasis by modulating tumor cell-platelet-endothelial cell interactions.Oncology letters · 2026Article
- Combining Experimental Validation and Network Pharmacology to Reveal the Action Mechanism of Panax Notoginseng-Radix Salviae on Atherosclerosis.Journal of inflammation research · 2025Article
- Research Progress on Natural Plant Molecules in Regulating the Blood-Brain Barrier in Alzheimer's Disease.Molecules (Basel, Switzerland) · 2023Review
- Upregulation of ribosome complexes at the blood-brain barrier in Alzheimer's disease patients.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2022Article
- RadixBioMed research international · 2022Article
- Tanshinone Ameliorates Glucocorticoid-Induced Bone LossFrontiers in cell and developmental biology · 2022Article
- Natural Compounds as Medical Strategies in the Prevention and Treatment of Psychiatric Disorders Seen in Neurological Diseases.Frontiers in pharmacology · 2021Review
- Neuroprotective effects of ZL006 in AβNeural regeneration research · 2020Article
- Sodium Tanshinone IIA Silate Exerts Microcirculation Protective Effects against Spinal Cord Injury In Vitro and In Vivo.Oxidative medicine and cellular longevity · 2020Article
- Tanshinone IIA: A Review of its Anticancer Effects.Frontiers in pharmacology · 2020Review
- Preliminary Studies on Liquiritin, Deoxyschizandrin, and Tanshinone II A as Potential Anti-Neurodegenerative Disease Agent: Determination by Reverse-Phase Liquid Chromatography in Tianwang Buxin Pills.Journal of analytical methods in chemistry · 2019Article
- Therapeutic Effects of Natural Drugs on Alzheimer's Disease.Frontiers in pharmacology · 2019Review
- High-Dose Tanshinone IIA Suppresses Migration and Proliferation While Promoting Apoptosis of Astrocytoma Cells Via Notch-1 Pathway.Neurochemical research · 2018Article
- Tanshinone‑IIA attenuates the deleterious effects of oxidative stress in osteoporosis through the NF‑κB signaling pathway.Molecular medicine reports · 2018Article
- Tanshinone IIA Inhibits Glutamate-Induced Oxidative Toxicity through Prevention of Mitochondrial Dysfunction and Suppression of MAPK Activation in SH-SY5Y Human Neuroblastoma Cells.Oxidative medicine and cellular longevity · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Therapeutic approach for Alzheimer's disease (AD) is still deficient. To find active compounds from herbal medicine is of interest in the alleviation of AD symptoms. This study aimed to investigate the protective effects of Tanshinone IIA (TIIA) on memory performance and synaptic plasticity in a transgenic AD model at the early phase. 25-100 mg/kg TIIA (intraperitoneal injection, i.p.) was administered to the six-month-old APP and PS1 transgenic mice for 30 consecutive days. After treatment, spatial memory, synaptic plasticity, and related mechanisms were investigated. Our result showed that memory impairment in AD mice was mitigated by 50 and 100 mg/kg TIIA treatments. Hippocampal long-term potentiation was impaired in AD model but rescued by 100 mg/kg TIIA treatment. Mechanically, TIIA treatment reduced the accumulations of beta-amyloid 1-42, C-terminal fragments (CTFs), and p-Tau in the AD model. TIIA did not affect basal BDNF but promoted depolarization-induced BDNF synthesis in the AD mice. Taken together, TIIA repairs hippocampal LTP and memory, likely, through facilitating the clearance of AD-related proteins and activating synaptic BDNF synthesis. TIIA might be a candidate drug for AD treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.